Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the google-analytics-dashboard-for-wp domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home3/moder9lh/public_html/wp-includes/functions.php on line 6121

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the cryout-serious-slider domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home3/moder9lh/public_html/wp-includes/functions.php on line 6121
Skanray Technologies files draft papers for Rs 400-crore IPO -
April 18, 2025
Shankray Image for News

The company may consider a pre-IPO placement of shares worth Rs 350 crore, including a fresh issue of a share of Rs 150 crore and a share sale by existing shareholders of up to Rs 200 crore

Medical devices manufacturer Skanray Technologies has filed its draft red herring prospectus (DRHP) with the markets regulator Sebi for its initial public offering (IPO) and is looking to raise Rs 400 crore, reports said. 

The IPO will include a secondary share sale, wherein its promoters and existing private equity investor Ascent Capital are expected to sell a part of their stakes, according to a report in Mint.

The company may consider a pre-IPO placement of shares worth Rs 350 crore, including a fresh issue of a share of Rs 150 crore and a share sale by existing shareholders of up to Rs 200 crore, the report added.

The company is in the business of manufacturing medical equipment, including patient monitoring systems, high-frequency X-ray devices, ventilators and critical care devices.

The company operates two US Food and Drug Administration-approved manufacturing facilities in Mysuru, and one in Bologna, Italy.

Skanray’s revenue in 5M FY21 was at Rs 88.8 crore (provisional figures), registering a growth of 138.3 per cent YoY, led by healthy demand across products.

Leave a Reply

Your email address will not be published. Required fields are marked *